Does gabapentin provide benefit for patients with knee osteoarthritis (OA)? A benefit-harm and cost-effectiveness analysis
Authors' conclusion
Incorporating gabapentin into care for patients with knee OA does not appear to offer good value.
Study context
- Population
- Simulated patients with knee OA
- Comparison
- Usual care, gabapentin sparing vs targeted gabapentin vs universal gabapentin plus usual care
- Outcome
- Cumulative QALYs, lifetime direct medical costs and incremental cost-effectiveness ratios (ICERs)
- Follow-up
- Lifetime
Methodological detailsMonte Carlo simulation model, Osteoarthritis Policy Model, benefit-harm analysis, lifetime horizon, discounted at 3% annually, sensitivity analyses
- Monte Carlo simulation model
- Osteoarthritis Policy Model
- Benefit-harm analysis
- Lifetime horizon
- Discounted at 3% annually
- Sensitivity analyses
Main finding
As reported in the abstract
Costs and QALYs
Cost increase
689 $
Targeted gabapentin (TG) vs usual care, gabapentin sparing (UC-GS) · QALY reduction of 0.012
Further cost increase
1,868 $
UG vs TG · 0.036 QALY decrease
Further findings
Sensitivity analyses
- Lowest TG ICER, with modified PainDETECT questionnaire (mPD-Q) specificity 100% and AE rate 0%
- $53,000/QALY
- Results robust to plausible changes in input parameters
Original publication
Does gabapentin provide benefit for patients with knee OA? A benefit-harm and cost-effectiveness analysis. Osteoarthritis Cartilage. Published 19 November 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →